{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-056017","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.388816+00:00","generated_at":"2026-06-03T00:49:26.099039+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organon Q1 2024 revenue up 5% to $1.62B; adjusted EPS $1.22, up 13% YoY; 2024 guidance reaffirmed","bullets":["Q1 revenue $1,622M (+5% as-reported, +7% constant currency); net income $201M (+14% YoY).","GAAP diluted EPS $0.78; non-GAAP adjusted diluted EPS $1.22 (+13% YoY); includes $0.05 IPR&D/milestone charge.","Women's Health revenue +11% on Nexplanon (+34% ex-FX); Biosimilars +46% led by Hadlima ($30M vs $5M).","Adjusted EBITDA $538M, margin 33.2%; full-year 2024 financial guidance ranges affirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-056017","json":"https://secwatch.observer/filing/0001104659-24-056017.json","markdown":"https://secwatch.observer/filing/0001104659-24-056017.md","text":"https://secwatch.observer/filing/0001104659-24-056017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924056017/0001104659-24-056017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924056017/tm2413293d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:49:26.099039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9d1f565c930bb2a8fd2facf870b95f623f0254e","claim":"Organon & Co. reported the first quarter ended March 31, 2024 results: revenue $1,622 million, net income $201 million, EPS $0.78. Guidance reaffirmed.","evidence_excerpt":"First quarter 2024 revenue of $1,622 million, up 5% on an as-reported basis and 7% at constant currency • First quarter 2024 diluted earnings per share of $0.78 and non-GAAP Adjusted diluted earnings per share of $1.22; both reported and non-GAAP Adjusted diluted earnings per share include $15 million expense, or $(0.05) per share, for acquired in-process research and development (IPR&D) and milestones • First quarter 2024 net income of $201 million and Adjusted EBITDA (non-GAAP) of $538 million • Full year 2024 financial guidance ranges affirmed","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924056017/0001104659-24-056017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$1,622 million"},{"label":"Net income","value":"$201 million"},{"label":"EPS","value":"$0.78"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}